FDA’s top drug regulator retiring after three weeks, citing concerns that Commissioner Makary’s plans to speed approvals and exclude career scientists may be illegal.
Predecessor left amid "petty revenge" scandal
Read the full story at Ars Technica
From the December 2, 2025 GovBrief, every story that day in one place.